|
1
|
Calvert PM and Frucht H: The genetics of
colorectal cancer. Ann Intern Med. 137:603–612. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dong C, Davis RJ and Flavell RA: MAP
kinases in the immune response. Annu Rev Immunol. 20:55–72. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lewis TS, Shapiro PS and Ahn NG: Signal
transduction through MAP kinase cascades. Adv Cancer Res.
74:49–139. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Troppmair J, Bruder JT, Munoz H, et al:
Mitogen-activated protein kinase/extracellular signal-regulated
protein kinase activation by oncogenes, serum, and
12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary
for transformation. J Biol Chem. 269:7030–7035. 1994.PubMed/NCBI
|
|
6
|
Hoshino R, Chatani Y, Yamori T, et al:
Constitutive activation of the 41-/43-kDa mitogen-activated protein
kinase signaling pathway in human tumors. Oncogene. 18:813–822.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Remacle-Bonnet MM, Garrouste FL, Heller S,
et al: Insulin-like growth factor-I protects colon cancer cells
from death factor-induced apoptosis by potentiating tumor necrosis
factor alpha-induced mitogen-activated protein kinase and nuclear
factor kappaB signaling pathways. Cancer Res. 60:2007–2017.
2000.PubMed/NCBI
|
|
8
|
Wang X, Wang Q, Hu W and Evers BM:
Regulation of phorbol ester-mediated TRAF1 induction in human colon
cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway.
Oncogene. 23:1885–1895. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ukegawa JI, Takeuchi Y, Kusayanagi S and
Mitamura K: Growth-promoting effect of muscarinic acetylcholine
receptors in colon cancer cells. J Cancer Res Clin Oncol.
129:272–278. 2003.PubMed/NCBI
|
|
10
|
Vial E and Marshall CJ: Elevated ERK-MAP
kinase activity protects the FOS family member FRA-1 against
proteasomal degradation in colon carcinoma cells. J Cell Sci.
116:4957–4963. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Im E and Martinez JD: Ursodeoxycholic acid
(UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via
modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells.
J Nutr. 134:483–486. 2004.PubMed/NCBI
|
|
12
|
Sebolt-Leopold JS, Dudley DT, Herrera R,
et al: Blockade of the MAP kinase pathway suppresses growth of
colon tumors in vivo. Nat Med. 5:810–816. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeung K, Seitz T, Li S, et al: Suppression
of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature.
401:173–177. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HS, Kim GY, Lim SJ and Kim YW:
Expression of Raf-1 kinase inhibitory protein in extrahepatic bile
duct carcinoma. Korean J Pathol. 44:234–242. 2010. View Article : Google Scholar
|
|
15
|
Kim HS, Kim GY, Lim SJ and Kim YW: Loss of
Raf-1 kinase inhibitory protein in pancreatic ductal
adenocarcinoma. Pathology. 42:655–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim HS, Kim GY, Lim SJ and Kim YW: Raf-1
kinase inhibitory protein expression in thyroid carcinomas. Endocr
Pathol. 21:253–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HS, Kim GY, Lim SJ, Park YK and Kim
YW: Reduced expression of Raf-1 kinase inhibitory protein is a
significant prognostic marker in patients with gallbladder
carcinoma. Hum Pathol. 41:1609–1616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim HS, Lee SH, Won KY, et al: Expression
of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of
Vater. Virchows Arch. 460:61–68. 2012. View Article : Google Scholar
|
|
19
|
Kim HS, Park SJ, Lee KY, Park YK and Kim
YW: Reduced Raf-1 kinase inhibitor protein expression predicts less
favorable outcomes in patients with hepatic colorectal metastasis.
Oncol Rep. 28:161–171. 2012.PubMed/NCBI
|
|
20
|
Kim HS, Won KY, Kim GY, et al: Reduced
expression of Raf-1 kinase inhibitory protein predicts regional
lymph node metastasis and shorter survival in esophageal squamous
cell carcinoma. Pathol Res Pract. 208:292–299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papin C, Denouel-Galy A, Laugier D,
Calothy G and Eychene A: Modulation of kinase activity and
oncogenic properties by alternative splicing reveals a novel
regulatory mechanism for B-Raf. J Biol Chem. 273:24939–24947. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trakul N, Menard RE, Schade GR, Qian Z and
Rosner MR: Raf kinase inhibitory protein regulates Raf-1 but not
B-Raf kinase activation. J Biol Chem. 280:24931–24940. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Royuela M, Arenas MI, Bethencourt FR, et
al: Regulation of proliferation/apoptosis equilibrium by
mitogen-activated protein kinases in normal, hyperplastic, and
carcinomatous human prostate. Hum Pathol. 33:299–306. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhuang L, Lee CS, Scolyer RA, et al:
Activation of the extracellular signal regulated kinase (ERK)
pathway in human melanoma. J Clin Pathol. 58:1163–1169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Corn BW, Kovner F, Bek S, et al: ERK
signaling in colorectal cancer: a preliminary report on the
expression of phosphorylated ERK and the effects of radiation
therapy. Am J Clin Oncol. 31:255–258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brabletz T, Jung A, Reu S, et al: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bates RC and Mercurio AM: The
epithelial-mesenchymal transition (EMT) and colorectal cancer
progression. Cancer Biol Ther. 4:365–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu F, Zykova TA, Kang BS, et al:
Bidirectional signals transduced by TOPK-ERK interaction increase
tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology.
133:219–231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Levidou G, Saetta AA, Gigelou F, et al:
ERK/pERK expression and B-raf mutations in colon adenocarcinomas:
correlation with clinicopathological characteristics. World J Surg
Oncol. 10:472012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klemke RL, Cai S, Giannini AL, et al:
Regulation of cell motility by mitogen-activated protein kinase. J
Cell Biol. 137:481–492. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McCawley LJ, Li S, Wattenberg EV and
Hudson LG: Sustained activation of the mitogen-activated protein
kinase pathway. A mechanism underlying receptor tyrosine kinase
specificity for matrix metalloproteinase-9 induction and cell
migration. J Biol Chem. 274:4347–4353. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kajanne R, Miettinen P, Mehlem A, et al:
EGF-R regulates MMP function in fibroblasts through MAPK and AP-1
pathways. J Cell Physiol. 212:489–497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vial E, Sahai E and Marshall CJ: ERK-MAPK
signaling coordinately regulates activity of Rac1 and RhoA for
tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Viala E and Pouysségur J: Regulation of
tumor cell motility by ERK mitogen-activated protein kinases. Ann
NY Acad Sci. 1030:208–218. 2004. View Article : Google Scholar
|
|
35
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie L, Law BK, Chytil AM, et al:
Activation of the Erk pathway is required for TGF-beta1-induced EMT
in vitro. Neoplasia. 6:603–610. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu X, Noh SJ, Zhou G, Dixon JE and Guan
KL: Selective activation of MEK1 but not MEK2 by A-Raf from
epidermal growth factor-stimulated Hela cells. J Biol Chem.
271:3265–3271. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gardner AM, Vaillancourt RR, Lange-Carter
CA and Johnson GL: MEK-1 phosphorylation by MEK kinase, Raf, and
mitogen-activated protein kinase: analysis of phosphopeptides and
regulation of activity. Mol Biol Cell. 5:193–201. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ballantyne GH and Quin J: Surgical
treatment of liver metastases in patients with colorectal cancer.
Cancer. 71(Suppl): 4252–4266. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nordlinger B, Vaillant JC, Guiguet M, et
al: Survival benefit of repeat liver resections for recurrent
colorectal metastases: 143 cases. Association Francaise de
Chirurgie. J Clin Oncol. 12:1491–1496. 1994.PubMed/NCBI
|
|
42
|
Petrowsky H, Gonen M, Jarnagin W, et al:
Second liver resections are safe and effective treatment for
recurrent hepatic metastases from colorectal cancer: a
bi-institutional analysis. Ann Surg. 235:863–871. 2002. View Article : Google Scholar : PubMed/NCBI
|
